|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.77 BRL | +10.99% |
|
+8.62% | +207.44% |
| Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
| Apr. 17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
Biomm S.A. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was BRL 34.28 million compared to BRL 25.43 million a year ago. Net loss was BRL 17.93 million compared to BRL 20.98 million a year ago.
Basic loss per share from continuing operations was BRL 0.22 compared to BRL 0.29 a year ago. Diluted loss per share from continuing operations was BRL 0.22.
| 1st Jan change | Capi. | |
|---|---|---|
| +207.44% | 310M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.43% | 22.18B | |
| -16.67% | 21.2B | |
| -8.68% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
BIOMM S.A. 
